
A 1.6-million-birth analysis finds that adoption of a 2016 trial's antibiotic protocol climbed sharply in US hospitals, with a drop in infection rates.
M.D. Anderson Cancer Center in Houston is testing RFID on two medications, Neupogen (filgrastim, Amgen) and Procrit (epoetin alfa, Ortho Biotech).






